Cyclooxygenase-2 inhibition in colon experimental carcinogenesis
| Autor: | A. Plaza Martínez, A. Gamundí Gamundí, J. F. Noguera Aguilar, C. Tortajada Collado, J Ibarra de la Rosa, I. Amengual Antich, J. J. Pujol Tugores |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
medicine.medical_specialty ASA Adenocarcinoma medicine.disease_cause Colon tumors Gastroenterology Rats Sprague-Dawley Lactones Internal medicine medicine Dimethylhydrazine Animals Sulfones Rofecoxib Carcinogen Aspirin Cyclooxygenase 2 Inhibitors biology business.industry General Medicine Colorectal cancer digestive system diseases 1 2-Dimethylhydrazine Rats Colon carcinogenesis Cyclooxygenase Disease Models Animal Cyclooxygenase 2 Colonic Neoplasms Colon tissue biology.protein Rat Carcinogenesis business medicine.drug |
| Zdroj: | Revista Española de Enfermedades Digestivas v.97 n.9 2005 SciELO España. Revistas Científicas Españolas de Ciencias de la Salud instname |
| Popis: | Background: an overexpression of cyclooxygenase-2 (COX-2) has been seen in colon tumors; therefore, COX-2 specific inhibitors may be used as preventive agents. The aim of this study was to investigate the effect of both selective and non-selective COX-2 inhibitors on the incidence of colonic tumors in a model of chemical carcinogenesis in the rat. Design: experimental study with 65 male Sprague-Dawley rats randomly assigned to one of four groups: (a) control (n = 20), with chemical carcinogenesis using 1-2 dimethylhydrazine (1-2 DMH); (b) acetylsalicylic acid (ASA) (n = 15), with chemical carcinogenesis and the addition of ASA at 30 mg/kg; (c) low-dose rofecoxib (n = 15), with chemical carcinogenesis and the addition of rofecoxib at a dose of 1.2 mg/kg; (d) high-dose rofecoxib (n = 15), with carcinogenesis and the addition of rofecoxib at 3 mg/kg. Carcinogenic induction was performed with 1-2 DMH at a weekly dose of 25 mg/kg for 18 weeks. The main parameter evaluated was percentage of neoplastic colonic tissue, which relates tumor surface area to colon surface area. Results: rofecoxib at a dose of 3 mg/kg significantly reduced chemical colon carcinogenesis in rats (p < 0.01). Rofecoxib in lower doses had the same effect on adenomas (p < 0.05) with no effect on adenocarcinomas. Rofecoxib reduced COX-2 expression in tumoral tissue from adenomas and adenocarcinomas (p < 0.01). Conclusions: rofecoxib prevents chemical colon carcinogenesis in the rat, with a reduction of tumoral colonic percentage in adenocarcinomas and tumoral COX-2 expression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|